Search research articles
Contact Us
Filters
Showing results (21-30 of 206) with videos related to
Page
of 21
Sort By:
British Journal of Haematology
|
August 4, 2011
Hypereosinophilia in relapsed acute myeloid leukaemia
Anna Colpo, Daniel Boyer, Amir T Fathi
American Journal of Hematology
|
May 9, 2012
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia
Hossein Sadrzadeh, Robert Hasserjian, Amir T Fathi
Discovery Medicine
|
January 1, 2013
Infectious pathogens and hematologic malignancy
Hossein Sadrzadeh, Seyed M Abtahi, Amir T Fathi
Cancer Treatment Reviews
|
January 9, 2010
Exploiting cellular pathways to develop new treatment strategies for AML
Amir T Fathi, Steven Grant, Judith E Karp
Discovery Medicine
|
December 30, 2011
Molecular alterations underlying eosinophilic and mast cell malignancies
Hossein Sadrzadeh, Omar Abdel-Wahab, Amir T Fathi
Therapeutic Advances in Hematology
|
June 3, 2014
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A Wander, Mark J Levis, Amir T Fathi
Oncotargets and Therapy
|
June 22, 2018
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
Evan C Chen, Amir T Fathi, Andrew M Brunner
Protein & Cell
|
August 29, 2013
The evolving landscape in the therapy of acute myeloid leukemia
Grace L Peloquin, Yi-Bin Chen, Amir T Fathi
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 27, 2014
New molecular abnormalities and clonal architecture in AML: from reciprocal translocations to whole-genome sequencing
Timothy A Graubert, Andrew M Brunner, Amir T Fathi
Best Practice & Research. Clinical Haematology
|
December 6, 2020
A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition
Anita G Koshy, Naval G Daver, Amir T Fathi
Page
of 21
Search research articles
Search
Showing results (21-30 of 206) with videos related to
Sort By:
Page
of 21
British Journal of Haematology
|
August 4, 2011
Hypereosinophilia in relapsed acute myeloid leukaemia
Anna Colpo, Daniel Boyer, Amir T Fathi
American Journal of Hematology
|
May 9, 2012
Pure erythroid leukemia evolving from a therapy-related myelodysplastic syndrome secondary to treatment for chronic lymphocytic leukemia
Hossein Sadrzadeh, Robert Hasserjian, Amir T Fathi
Discovery Medicine
|
January 1, 2013
Infectious pathogens and hematologic malignancy
Hossein Sadrzadeh, Seyed M Abtahi, Amir T Fathi
Cancer Treatment Reviews
|
January 9, 2010
Exploiting cellular pathways to develop new treatment strategies for AML
Amir T Fathi, Steven Grant, Judith E Karp
Discovery Medicine
|
December 30, 2011
Molecular alterations underlying eosinophilic and mast cell malignancies
Hossein Sadrzadeh, Omar Abdel-Wahab, Amir T Fathi
Therapeutic Advances in Hematology
|
June 3, 2014
The evolving role of FLT3 inhibitors in acute myeloid leukemia: quizartinib and beyond
Seth A Wander, Mark J Levis, Amir T Fathi
Oncotargets and Therapy
|
June 22, 2018
Reformulating acute myeloid leukemia: liposomal cytarabine and daunorubicin (CPX-351) as an emerging therapy for secondary AML
Evan C Chen, Amir T Fathi, Andrew M Brunner
Protein & Cell
|
August 29, 2013
The evolving landscape in the therapy of acute myeloid leukemia
Grace L Peloquin, Yi-Bin Chen, Amir T Fathi
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
May 27, 2014
New molecular abnormalities and clonal architecture in AML: from reciprocal translocations to whole-genome sequencing
Timothy A Graubert, Andrew M Brunner, Amir T Fathi
Best Practice & Research. Clinical Haematology
|
December 6, 2020
A new era of immuno-oncology in acute myeloid leukemia - antibody-based therapies and immune checkpoint inhibition
Anita G Koshy, Naval G Daver, Amir T Fathi
Page
of 21